QUOTE AND NEWS
Benzinga  Mar 10  Comment 
In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a Buy rating and $21.00 price target. In the report, H.C. Wainwright & Co. noted, “Biocryst's...
Benzinga  Mar 10  Comment 
Analysts at UBS initiated coverage on shares of Concert Pharmaceuticals (NASDAQ: CNCE) with a “buy” rating. The target price for Concert Pharma is set to $25. Concert Pharma's shares closed at $14.88 on Friday. HC Wainwright initiated...
SeekingAlpha  Mar 10  Comment 
By Markus Aarnio: BioCryst Pharmaceuticals (BCRX) designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. (click to enlarge) Insider selling during the last 30 days Here is a table...
StreetInsider.com  Mar 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharma+%28BCRX%29+Reports+Publication+of+Extensive+BCX4430+Data/9234604.html for the full story.
SeekingAlpha  Feb 26  Comment 
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2013 Earnings Conference Call February 26, 2014 11:00 a.m. ET Executives Robert Bennett – VP, IR Jon Stonehouse – President and CEO Thomas Staab – SVP and CFO William Sheridan...
StreetInsider.com  Feb 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharmaceuticals+%28BCRX%29+and+HHS+Extend+Peramivir+Pact+/9218602.html for the full story.
StreetInsider.com  Feb 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/BioCryst+Pharma+%28BCRX%29+Posts+Q4+Loss+of+9cShare/9217333.html for the full story.
Benzinga  Feb 25  Comment 
zulily (NASDAQ: ZU) soared 10.81% to $47.47 in the pre-market trading after the company reported upbeat Q4 results. Cara Therapeutics (NASDAQ: CARA) surged 10.34% to $16.00 in the pre-market session after Stifel Nicolaus initiated coverage on...
Benzinga  Jan 27  Comment 
Analysts at Jefferies downgraded First Niagara Financial Group (NASDAQ: FNFG) from “outperform” to “hold.” The target price for First Niagara Financial Group has been raised from $12 to $19. First Niagara Financial's shares closed at $9.08...
Benzinga  Jan 21  Comment 
Analysts at ISI Group initiated coverage on shares of Intuitive Surgical (NASDAQ: ISRG) with a “strong buy” rating. The target price for Intuitive Surgical is set to $50. Intuitive Surgical's shares closed at $430.14 on Friday. Analysts at...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki